Vasostatins. Vascular targets.
Helle
K B
KB
Department of Physiology, University of Bergen, 5000 Bergen, Norway.
D020533:Angiogenesis Inhibitors / Q000502:physiology; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000502:physiology*; D002135:Calcium-Binding Proteins / Q000502:physiology*; D037282:Calreticulin; D002352:Carrier Proteins / Q000502:physiology; D053379:Chromogranin A; D002864:Chromogranins / Q000502:physiology; D019332:Endothelin-1 / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000502:physiology; D006801:Humans; D008833:Microcirculation / Q000187:drug effects / Q000502:physiology; D008955:Models, Cardiovascular; D009638:Norepinephrine / Q000494:pharmacology; D010446:Peptide Fragments / Q000502:physiology*; D011188:Potassium / Q000494:pharmacology; D012261:Ribonucleoproteins / Q000502:physiology*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology
D020533:Angiogenesis Inhibitors; D002135:Calcium-Binding Proteins; D037282:Calreticulin; D002352:Carrier Proteins; D053379:Chromogranin A; D002864:Chromogranins; D019332:Endothelin-1; D010446:Peptide Fragments; D012261:Ribonucleoproteins; C121986:vasostatin; C102106:vasostatin II; D011188:Potassium; D009638:Norepinephrine